Products

What will AGI do for Aminophenazone cyclamate?

This classification denotes an analgesic and antipyretic with the molecular formula C13H17N3O.C6H13NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RM5BP192F9, chemically known as 4-dimethylamino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one cyclohexylsulfamate but more generally known as aminophenazone cyclamate, which bears US NIH Compound Identifier 170322. European Medicines Agency schedules Aminophenazone cyclamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05443MIG. The term AMINOPHENAZONE CYCLAMATE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule aminophenazone cyclamate under HS 29331190. As of Q4 2014, AMINOPHENAZONE CYCLAMATE remains US FDA's Preferred Term for this commodity. Aminophenazone cyclamate bears US NLM identifiers UMLS ID C2346742 and NCI Concept Code C72104. SMILES: CC1C(C(=O)N(N1C)C2CCCCC2)N(C)C.C1CCC(CC1)NS(=O)(=O)O.

How AGI delivers it

Four ways AGI delivers for Aminophenazone cyclamate

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Aminophenazone cyclamate, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Aminophenazone cyclamate, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Aminophenazone cyclamate connects

measured by

  • Assay Puritymodel
  • Content Uniformitymodel
  • Dissolution Ratemodel